today
small
molecul
antivir
drug
avail
treatment
infect
herpesvirus
hiv
hbv
hcv
well
influenza
virus
ribavirin
broadspectrum
aspecif
antivir
approv
treatment
infect
respiratori
syncyti
viru
hcv
lassa
viru
yet
mani
virus
caus
lifethreaten
infect
consid
emerg
andor
neglect
drug
avail
ideal
potent
broadspectrum
ie
pangenu
panfamili
viru
activ
antivir
drug
develop
wherebi
one
drug
could
use
treatment
number
viral
infect
review
recent
evolut
search
inhibitor
emerg
neglect
rna
virus
yannick
debe
dirk
jochman
johan
neyt
today
small
molecul
antivir
drug
avail
treatment
infect
herpesvirus
hiv
hbv
hcv
well
influenza
virus
ribavirin
broadspectrum
aspecif
antivir
approv
treatment
infect
respiratori
syncyti
viru
hcv
lassa
viru
yet
mani
virus
caus
lifethreaten
infect
consid
emerg
andor
neglect
drug
avail
ideal
potent
broadspectrum
ie
pangenu
panfamili
viru
activ
antivir
drug
develop
wherebi
one
drug
could
use
treatment
number
viral
infect
review
recent
evolut
search
inhibitor
emerg
neglect
rna
virus
today
small
molecul
antivir
drug
avail
treatment
infect
herpesvirus
hiv
hbv
hcv
well
influenza
virus
year
discoveri
hiv
compound
formal
approv
treatment
aid
use
fixeddos
drug
combin
potent
highli
effect
welltoler
drug
also
avail
treatment
hbv
infect
hcv
two
proteas
inhibitor
recent
approv
number
directact
antivir
daa
develop
ultim
combin
appropri
drug
regim
potent
nucleo
ide
analog
acyclovir
ganciclovir
cidofovir
target
viral
polymeras
avail
treatment
herpesviru
infect
yet
novel
drug
target
viral
helicaseprimas
cmv
terminas
develop
influenza
viru
novel
neuraminidas
inhibitor
peramivir
laninamivir
octano
polymeras
inhibitor
favipiravir
develop
broadspectrum
inhibitor
ribavirin
approv
treatment
infect
respiratori
syncyti
viru
hcv
lassa
viru
conclus
larg
number
drug
avail
hiv
mani
drug
clinic
develop
treatment
chronic
hcv
infect
demonstr
even
virus
short
genom
mani
excel
molecular
target
exist
inhibit
viral
replic
yet
mani
virus
caus
lifethreaten
infect
man
drug
hand
treatment
emerg
andor
neglect
viral
pathogen
rna
genom
includ
virus
dengu
fever
viru
flavivirus
chikungunya
viru
enteroviru
rabi
viru
hev
coronavirus
arenavirus
bunyavirus
filovirus
although
well
feasibl
develop
potent
inhibitor
current
known
neglect
andor
emerg
virus
may
econom
viabl
option
therefor
ideal
potent
broadspectrum
drug
develop
use
treatment
varieti
viral
infect
possibl
nucleosid
analog
characterist
may
designeddiscov
altern
develop
drug
broadspectrum
antivir
activ
within
given
genu
famili
eg
broadspectrum
flaviviru
paramyxoviru
inhibitor
probabl
novel
potenti
highli
pathogen
rna
virus
emerg
futur
consid
instanc
recent
fatal
novel
coronavirusemc
broadspectrum
pangenu
panfamili
panrna
viru
inhibitor
hand
may
help
contain
futur
outbreak
review
provid
nonexhaust
overview
recent
develop
search
small
molecul
inhibitor
neglectedemerg
rna
virus
twofifth
world
popul
risk
dengu
infect
million
case
estim
occur
worldwid
everi
year
estim
peopl
sever
dengu
requir
hospit
year
larg
proport
children
result
fatal
outcom
affect
neither
vaccin
specif
antivir
treatment
likewis
antivir
avail
treatment
lifethreaten
infect
flavivirus
caus
yellow
fever
viru
japanes
enceph
viru
west
nile
viru
organ
genom
flavivirus
resembl
extent
relat
hcv
viral
serin
proteas
rnadepend
rna
polymeras
shown
excel
target
inhibit
viral
replic
vitro
infect
patient
far
flaviviru
proteas
inhibitor
potenc
compar
hcv
proteas
inhibitor
yet
identifi
particular
differ
characterist
structur
differ
proteas
may
reason
exhaust
review
flaviviru
proteas
target
design
inhibitor
recent
publish
second
nucleosid
well
nonnucleosid
polymeras
inhibitor
hcv
current
clinic
develop
exert
pangenotyp
antivir
activ
high
barrier
resist
nucleosid
polymeras
inhibitor
target
enzym
phosphoryl
metabolit
also
shown
exert
panserotyp
antidengu
viru
activ
vitro
dengu
mous
model
balipiravir
nucleosid
hcv
polymeras
inhibitor
evalu
potenti
activ
dengueinfect
patient
protect
activ
observ
lack
activ
balipiravir
probabl
ascrib
weak
vitro
potenc
molecul
denv
creat
pessim
regard
potenti
use
nucleosid
analog
treatment
dengu
hcv
larg
number
nonnucleosid
polymeras
inhibitor
report
least
differ
alloster
pocket
inhibit
enzym
activ
identifi
enzym
least
one
caviti
found
dengu
polymeras
may
potenti
serv
pocket
inhibitor
enzym
could
design
addit
flaviviru
gene
encod
besid
viral
polymeras
also
methyltransferas
mtase
respons
methyl
viral
cap
mtase
critic
viral
replic
therefor
repres
valid
target
antivir
therapeut
effort
ongo
develop
select
inhibitor
enzym
fourth
flaviviru
essenti
membraneassoci
viral
protein
homologu
hcv
shown
target
small
molecul
dengu
inhibitor
also
inhibitor
yellow
fever
viru
replic
report
target
recent
identifi
class
highli
potent
panserotyp
dengu
viru
inhibitor
target
unpublish
data
exact
mechan
molecul
target
therebi
inhibit
viral
replic
remain
elucid
despit
fact
precis
function
well
understood
protein
appear
akin
hcv
excel
target
design
potent
inhibitor
viral
replic
final
inhibit
host
factor
essenti
viru
replic
might
consid
instanc
inhibitor
dihydroorot
dehydrogenas
dhodh
enzym
requir
pyrimidin
biosynthesi
identifi
inhibitor
vitro
dengu
viru
replic
effect
dengu
virusinfect
mice
glycosyl
inhibitor
nnonyldeoxynojirimycin
celgosivir
shown
inhibit
dengu
viru
replic
misfold
activ
celgosivir
also
demonstr
dengu
mous
model
activ
current
explor
clinic
studi
celaden
drug
trial
url
http
wwwceladensg
design
appropri
clinic
trial
dengu
drug
might
challeng
howev
recent
recommend
design
trial
publish
enteroviru
genu
famili
picornavirida
compris
multipl
medic
import
pathogen
polioviru
probabl
best
known
global
polio
erad
initi
aim
erad
polio
globe
viru
still
remain
endem
nigeria
afghanistan
pakistan
effect
antivir
polioviru
may
essenti
complet
erad
wildtyp
circul
vaccinederiv
polioviru
enteroviru
emerg
major
pathogen
southeast
asia
past
year
viru
caus
handfootandmouth
diseas
young
children
may
also
result
lifethreaten
viral
enceph
also
enterovirus
may
caus
seriou
ill
includ
asept
mening
vaccin
except
polio
drug
avail
prevent
treatment
enterovir
infect
drug
urgent
await
although
multipl
compound
current
clinic
develop
none
receiv
market
author
thu
far
sever
molecul
capsid
binder
interfer
receptor
attach
cell
entri
andor
viru
uncoat
pleconaril
develop
oral
treatment
common
cold
accept
fda
safeti
concern
pleconaril
also
effect
enterovirus
sinc
trial
enterovir
sepsi
syndrom
nasal
spray
common
cold
symptom
asthma
exacerb
result
disclos
date
url
http
wwwclinicaltrialsgov
vapendavir
anoth
capsid
binder
clinic
develop
treatment
rhinoviru
infect
asthmat
patient
url
http
www
clinicaltrialsgov
recent
press
releas
biota
report
success
complet
phase
iib
studi
vapendavir
final
capsid
binder
investig
use
polioviru
erad
phase
ii
trial
current
ongo
sweden
assess
effect
viru
shed
inocul
oral
polioviru
vaccin
url
http
www
clinicaltrialsregistereu
main
drawback
capsid
binder
rather
easili
select
resist
enterovirus
toler
mutat
capsid
protein
quit
well
enterovir
proteas
pro
may
anoth
interest
drug
target
peptidomimet
pro
inhibitor
rupintrivir
elicit
panenteropanrhinoviru
activ
compound
effect
volunt
experiment
rhinoviru
infect
lack
efficaci
natur
infect
patient
oral
avail
analog
design
compound
clinic
develop
halt
despit
success
phase
studi
use
structurebas
drug
design
approach
class
broadspectrum
enterovir
pro
inhibitor
recent
develop
helicasentpas
constitut
anoth
promis
target
number
molecul
target
viral
protein
report
ahydroxybenzyl
benzimidazol
hbb
recent
identifi
class
highli
potent
panentero
panrhinoviru
compound
target
high
barrier
resist
highli
effect
enteroviru
infect
model
mice
unpublish
result
despit
fact
precis
mechan
compound
interact
remain
discov
protein
view
excel
target
develop
potent
panenteroviru
inhibitor
multifunct
protein
involv
replic
complex
format
sever
enteroviru
inhibitor
found
select
drugresist
mutat
exampl
enviroxim
enviroxim
evalu
clinic
trial
caus
gastrointestin
side
effect
fail
protect
natur
rhinoviru
infect
molecul
recent
shown
block
enteroviru
replic
direct
inhibit
host
enzym
kinas
iiib
recruit
replic
complex
resist
mutat
render
viru
independ
replic
wherea
viral
polymeras
proven
excel
target
inhibit
viral
replic
number
virus
includ
hiv
hcv
select
inhibitor
enteroviru
polymeras
far
report
recent
discov
class
nonnucleosid
broadspectrum
antienteroantirhinoviru
activ
target
viral
rnadepend
rna
polymeras
compet
templat
primer
van
der
linden
et
al
submit
public
chikungunya
viru
chikv
belong
genu
alphaviru
famili
togavirida
infect
associ
acut
patholog
character
fever
rash
arthralgia
care
still
limit
support
treatment
aim
allevi
infectioninduc
symptom
limit
vitro
antivir
activ
chloroquin
alphainterferon
ifna
ribavirin
demonstr
benefit
drug
observ
clinic
set
number
natur
product
terpenoid
compound
prostratin
approv
drug
phenothiazinyl
arbidol
shown
inhibit
vitro
chikv
replic
computeraid
design
result
identif
inhibitor
proteas
recent
demonstr
antiinfluenza
drug
favipiravir
inhibit
vitro
replic
chikv
includ
clinic
isol
result
protect
activ
anim
model
unpublish
data
four
coronavirus
cov
known
endem
human
popul
associ
mild
sever
respiratori
symptom
novel
cov
sever
acquir
respiratori
syndrom
sar
cov
caus
epidem
respiratori
diseas
almost
peopl
case
fatal
rate
sarscov
probabl
result
zoonot
event
bat
viru
jump
human
popul
directli
via
anoth
anim
novel
cov
discov
patient
saudi
arabia
day
viru
diagnos
patient
connect
differ
region
middleeast
die
one
case
also
evid
persontoperson
transmiss
health
protect
agenc
uk
url
http
wwwhpaorguknewscentrenationalpressreleas
associ
sever
respiratori
ill
potenti
outbreak
new
strain
high
transmiss
fatal
rate
urgent
need
inhibitor
cov
replic
far
small
molecul
antivir
yet
shown
activ
experiment
infect
model
clinic
set
two
cystein
proteas
resid
within
sarscov
polyprotein
papainlik
proteas
proteas
proteas
differ
inhibitor
discov
optim
despit
effort
structur
biolog
chemic
optim
best
inhibitor
current
effect
mm
rang
sarscov
viru
use
differ
host
cell
proteas
cellular
entri
inhibit
proteas
shown
block
entri
viru
vitro
assay
interestingli
one
host
cell
proteas
target
use
approach
also
pivot
replic
respiratori
virus
like
influenza
human
metapneumoviru
hmpv
inhibitor
sarscov
helicas
report
also
inhibit
vitro
replic
viru
recent
new
inhibitor
viral
helicas
discov
targetbas
screen
inhibit
vitro
replic
viru
hope
optim
class
may
deliv
potent
compound
hepevirida
famili
transmit
faecoor
infect
asymptomat
especi
young
children
usual
present
mild
acut
hepat
nevertheless
fulmin
hepat
requir
liver
transplant
occur
particularli
pregnant
women
hev
genotyp
endem
develop
countri
host
rang
restrict
human
genotyp
zoonos
major
reservoir
domest
pig
caus
sporad
infect
worldwid
link
consumpt
undercook
pig
deer
meat
even
though
recombin
vaccin
hev
develop
approv
china
yet
hev
caus
million
infect
death
stillbirth
annual
experi
hepat
e
treatment
limit
larg
restrict
chronic
infect
transplant
patient
first
consider
lower
immunosuppress
therapi
clear
infect
patient
ribavirin
monotherapi
report
success
chronic
hepat
e
patient
anemia
frequent
side
effect
necessit
dose
reduct
number
case
patient
treat
month
longer
ribavirin
contraind
pregnanc
pegifna
treatment
anoth
option
success
combin
therapi
pegifna
ribavirin
report
chronic
hevinfect
patient
ribavirin
also
substanti
decreas
hev
rna
level
case
sever
acut
hepat
e
nevertheless
urgent
need
efficaci
nontox
treatment
hev
infect
use
contain
outbreak
safe
pregnant
woman
first
effici
cell
cultur
system
hev
describ
recent
instrument
develop
potent
select
inhibitor
sever
paramyxovirus
caus
diseas
man
human
respiratori
syncyti
viru
rsv
hmpv
parainfluenza
viru
broadli
preval
respiratori
pathogen
nipah
hendra
virus
highli
pathogen
paramyxovirus
emerg
bat
within
past
two
decad
capabl
caus
fatal
diseas
human
would
seem
prudent
develop
drug
treatment
rsv
hmpv
infect
aim
gener
drug
elicit
broadspectrum
antiparamyxoviru
activ
could
thu
deploy
treat
infect
nipah
hendra
highli
pathogen
paramyxovirus
would
emerg
ribavirin
current
drug
licens
treat
rsv
infect
clinic
efficaci
remain
unclear
major
report
smallmolecul
antivir
target
rsv
entri
step
block
fusion
protein
microdos
therapeut
current
one
advanc
rsv
fusion
inhibitor
current
enter
phase
iia
johnson
johnson
anoth
fusion
inhibitor
caus
local
disturb
fprotein
postfus
conform
molecul
reduc
rsv
replic
consequenti
lung
inflamm
mice
phase
studi
yet
anoth
fusion
inhibitor
biota
anticip
start
biota
url
http
wwwbiotapharmacom
page
efficaci
compound
shown
two
nonclin
model
human
rsv
infect
gilead
scienc
recent
initi
phase
ii
safeti
efficaci
rsv
challeng
studi
novel
molecul
undefin
mechan
healthi
volunt
url
http
wwwclinicaltrialsgov
addit
nonnucleosid
inhibitor
rsv
replic
report
inhibit
guanylyl
cap
viral
transcript
final
alio
biopharma
report
discoveri
nucleosid
analog
potent
inhibit
rsv
replic
target
viral
polymeras
compani
plan
bring
oral
bioavail
analog
clinic
trial
aloi
biopharma
url
http
wwwaliosbiopharma
com
rabi
caus
nearli
fatal
encephalomyel
human
effect
vaccin
avail
mani
peopl
risk
remain
unvaccin
current
strategi
postexposur
prophylaxi
involv
infiltr
wound
human
rabi
immunoglobulin
vaccin
year
estim
peopl
mani
children
die
rabi
infect
recent
year
treatment
protocol
known
milwauke
protocol
set
involv
induct
coma
treatment
ketamin
neuroprotect
anesthet
put
antirabi
activ
well
amantadin
ribavirin
although
amantadin
ribavirin
inhibit
vitro
replic
viru
extent
activ
never
demonstr
experiment
infect
model
clinic
set
despit
fact
milwauke
protocol
use
sever
time
effect
remain
controversi
potent
inhibitor
rabi
replic
penetr
brain
urgent
need
drug
might
help
patient
surviv
recov
even
neurolog
complic
alreadi
develop
limit
number
phylogenet
distinct
virus
belong
arenavirida
bunyavirida
filovirida
famili
caus
sever
often
lethal
hemorrhag
fever
syndrom
lassa
viru
arenavirida
respons
larg
number
death
west
africa
ribavirin
licens
antivir
report
activ
lassa
viru
also
effect
arenavirus
new
world
junin
machupo
viru
favipiravir
develop
treatment
influenza
viru
infect
also
shown
efficaci
experiment
mous
hamster
model
arenaviru
broadspectrum
antirna
viru
drug
could
thu
potenti
use
offlabel
approv
treatment
influenza
viru
infect
treatment
lifethreaten
arenaviru
infect
larg
screen
effort
use
lentivir
pseudotyp
lassa
viru
envelop
glycoprotein
class
compound
identifi
inhibit
lassa
arenaviru
entri
lead
compound
efficaci
lethal
lasv
guinea
pig
model
superior
activ
compar
ribavirin
latest
develop
search
inhibitor
arenaviru
recent
review
rift
valley
fever
rvf
caus
bunyaviru
affect
ungul
also
caus
diseas
human
current
fdaapprov
antivir
treatment
rvf
ribavirin
shown
efficaci
anim
model
system
rvf
indic
compassion
use
guidelin
event
emerg
favipiravir
analog
shown
efficaci
rvf
cell
cultur
surrog
anim
model
crimeancongo
hemorrhag
fever
cchf
caus
cchf
viru
anoth
bunyaviru
viru
caus
fatal
infect
transmit
bite
tick
contact
patient
cchf
acut
phase
infect
contact
blood
tissu
virem
livestock
report
case
fatal
rate
rang
number
observ
studi
indic
treatment
antivir
drug
ribavirin
benefici
cchf
placebocontrol
trial
perform
filovirus
ebolaviru
ebov
marburg
caus
sever
hemorrhag
fever
high
case
fatal
rate
neither
vaccin
antivir
treatment
current
avail
although
vaccin
would
greatli
appreci
potent
fastact
antivir
drug
requir
well
consid
sporad
natur
infect
rapid
diseas
progress
earliest
report
inhibitor
filoviru
replic
carbocycl
function
block
host
enzym
sadenosyllhomocystein
hydrolas
therebi
prevent
methyl
cap
molecul
protect
mice
experiment
ebov
infect
anoth
class
filoviru
inhibitor
target
viru
entri
instanc
compound
block
bind
ebov
glycoprotein
gp
receptor
niemannpick
benzodiazepinederiv
inhibit
entri
bind
pocket
gp
molecul
detail
regard
mechan
action
miss
exampl
broadspectrum
antivir
compound
three
inhibitor
protect
lethal
ebov
mous
model
last
antivir
molecul
report
recent
antioxid
result
activ
infect
model
well
